The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Comprehensive Analysis of UGT1A Polymorphisms Predictive for Pharmacokinetics and Treatment Outcome in Patients With Non–Small-Cell Lung Cancer Treated With Irinotecan and Cisplatin
Abstract
Purpose: To determine whether uridine diphosphate-glucuronosyltransferase 1A1, UGT1A7, and UGT1A9 polymorphisms affect the pharmacokinetics (PK) of irinotecan and treatment outcome of Korean patients with advanced non–small-cell lung cancer (NSCLC). Methods: Eighty-one patients with advanced NSCLC were treated with irinotecan (80 mg/m 2) on day 1 and 8 and cisplatin (60 mg/m 2) on day 1 intravenously of each 3-week cycle. Genomic DNA was extracted from peripheral blood and genotyped using direct sequencing. We analyzed the association of UGT1A genotypes with irinotecan PK and clinical outcomes. All statistical tests were two-sided. Results: In genotype-PK association analysis, UGT1A1*6/*6 (n = 6), UGT1A7*3/*3 (n = 6), and UGT1A9-118(dT)9/9(n = 11) were associated with significantly lower area under the time-concentration curve (AUC) SN-38G to SN-38 (AUC SN-38G/AUC SN-38) ratio (P = .002, P = .009, and P = .001, respectively). In linkage disequilibrium analysis, the UGT1A7 variants were highly linked with the UGT1A1*6 (D′ = 0.85, r 2= 0.63) and UGT1A9*22 (D′ = 0.95, r 2= 0.88), which was substantiated in haplotype analysis. Patients with UGT1A1*6/*6 had lower tumor response and higher incidence of severe neutropenia. UGT1A9-118(dT)9/9 also showed a trend for high incidence of severe diarrhea, but not tumor response. In survival analysis, patients with UGT1A1*6/*6 had significantly shorter progression-free survival (P = .001) and overall survival (P = .017). Conclusion: These findings suggest that UGT1A1*6 and UGT1A9*22 genotypes may be important for SN-38 glucuronidation and associate with irinotecan-related severe toxicity. Specifically, UGT1A1*6 might be useful for predicting tumor response and survival outcome of Korean patients with NSCLC treated with irinotecan-based chemotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968
Irinotecan plus Fluorouracil and Leucovorin for Metastatic Colorectal Cancer
Saltz, L. B., Cox, J. V., Blanke, C., Rosen, L. S., Fehrenbacher, L., Moore, M. J., Maroun, J. A., Ackland, S. P., Locker, P. K., Pirotta, N., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200009283431302 · Cited by 3,005
Maximum-likelihood estimation of molecular haplotype frequencies in a diploid population.
(1995) · Molecular Biology and Evolution · doi:10.1093/oxfordjournals.molbev.a040269 · Cited by 1,950
Bosma, P. J., Chowdhury, J. R., Bakker, C., Gantla, S., de Boer, A., Oostra, B. A., Lindhout, D., Tytgat, G. N. J., Jansen, P. L. M., Elferink, R. P. J. O., et al. (1995) · New England Journal of Medicine · doi:10.1056/nejm199511023331802 · Cited by 1,447
Innocenti, F., Undevia, S. D., Iyer, L., Xian Chen, P., Das, S., Kocherginsky, M., Karrison, T., Janisch, L., Ramírez, J., Rudin, C. M., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.07.173 · Cited by 964
Clinical pharmacokinetics and metabolism of irinotecan (CPT-11).
Mathijssen, R. H. J., van Alphen, R. J., Verweij, J., Loos, W. J., Nooter, K., Stoter, G., & Sparreboom, A. (2001) · PubMed · Cited by 740
UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity
Iyer, L., Das, S., Janisch, L., Wen, M., Ramírez, J., Karrison, T., Fleming, G. F., Vokes, E. E., Schilsky, R. L., & Ratain, M. J. (2002) · The Pharmacogenomics Journal · doi:10.1038/sj.tpj.6500072 · Cited by 720
On measures of gametic disequilibrium.
Lewontin, R. C. (1988) · Genetics · doi:10.1093/genetics/120.3.849 · Cited by 712
Iyer, L., King, C. D., Whitington, P. F., Green, M. D., Roy, S. K., Tephly, T. R., Coffman, B. L., & Ratain, M. J. (1998) · Journal of Clinical Investigation · doi:10.1172/jci915 · Cited by 686
Metabolic fate of irinotecan in humans: correlation of glucuronidation with diarrhea.
Gupta, E., Lestingi, T. M., Mick, R., Ramirez, J., Vokes, E. E., & Ratain, M. J. (1994) · PubMed · Cited by 501
Rothenberg, M. L., Meropol, N. J., Poplin, E. A., Van Cutsem, E., & Wadler, S. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.18.3801 · Cited by 425
The role of hepatic and extrahepatic UDP-glucuronosyltransferases in human drug metabolism*†
Fisher, M. B., Paine, M. F., Strelevitz, T. J., & Wrighton, S. A. (2001) · Drug Metabolism Reviews · doi:10.1081/dmr-120000653 · Cited by 375
Gagné, J.-F., Montminy, V., Belanger, P., Journault, K., Gaucher, G., & Guillemette, C. (2002) · Molecular Pharmacology · doi:10.1124/mol.62.3.608 · Cited by 346
Carlini, L. E., Meropol, N. J., Bever, J., Andria, M. L., Hill, T., Gold, P., Rogatko, A., Wang, H., & Blanchard, R. L. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.1226.11.3 · Cited by 262
Irinotecan pathway genotype analysis to predict pharmacokinetics.
Mathijssen, R. H. J., Marsh, S., Karlsson, M. O., Xie, R., Baker, S. D., Verweij, J., Sparreboom, A., & McLeod, H. L. (2003) · PubMed · Cited by 258
SAI, K. (2004) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2004.01.010 · Cited by 257
Yamamoto, K., Satō, H., Fujiyama, Y., Doida, Y., & Bamba, T. (1998) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/s0925-4439(98)00013-1 · Cited by 191
Recommendation for Caution with Irinotecan, Fluorouracil, and Leucovorin for Colorectal Cancer
(2001) · New England Journal of Medicine · doi:10.1056/nejm200107123450213 · Cited by 191
Villeneuve, L., Girard, H., Fortier, L.-C., Gagné, J.-F., & Guillemette, C. (2003) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.103.054072 · Cited by 186
Gupta, E., Mick, R., Ramirez, J., Wang, X., Lestingi, T. M., Vokes, E. E., & Ratain, M. J. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.4.1502 · Cited by 182
Guillemette, C., Ritter, J. K., Auyeung, D. J., Kessler, F. K., & Housman, D. E. (2000) · Pharmacogenetics · doi:10.1097/00008571-200010000-00006 · Cited by 169
Tobacco Carcinogen-Detoxifying Enzyme UGT1A7 and Its Association With Orolaryngeal Cancer Risk
Zheng, Z., Park, J. Y., Guillemette, C., et al. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.18.1411 · Cited by 156
for the CPT-11 Lung Cancer Study Group West, Negoro, S., Masuda, N., Takada, Y., Sugiura, T., Kudoh, S., Katakami, N., Ariyoshi, Y., Ohashi, Y., Niitani, H., et al. (2003) · British Journal of Cancer · doi:10.1038/sj.bjc.6600725 · Cited by 151
Polymorphisms of the human UDP-glucuronosyltransferase (UGT) 1A7 gene in colorectal cancer
Strassburg, C. P. (2002) · Gut · doi:10.1136/gut.50.6.851 · Cited by 136
Fisher, M. B., VandenBranden, M. R., Findlay, K. A. B., Burchell, B., Thummel, K. E., Hall, S. D., & Wrighton, S. A. (2000) · Pharmacogenetics · doi:10.1097/00008571-200011000-00007 · Cited by 133
Lessons Learned from the Irinotecan Metabolic Pathway
Ma, M., & McLeod, H. L. (2003) · Current Medicinal Chemistry · doi:10.2174/0929867033368619 · Cited by 122
Yamanaka, H., Nakajima, M., Katoh, M., Hara, Y., Tachibana, O., Yamashita, J., McLeod, H. L., & Yokoi, T. (2004) · Pharmacogenetics · doi:10.1097/00008571-200405000-00008 · Cited by 119
Influence of Genetic Variants in UGT1A1 and UGT1A9 on the In Vivo Glucuronidation of SN‐38
Paoluzzi, L., Singh, A. S., Price, D. K., Danesi, R., Mathijssen, R. H. J., Verweij, J., Figg, W. D., & Sparreboom, A. (2004) · The Journal of Clinical Pharmacology · doi:10.1177/0091270004267159 · Cited by 113
Haplotypes of variants in the UDP-glucuronosyltransferase1A9 and 1A1 genes
Innocenti, F., Liu, W., Chen, P., Desai, A. A., Das, S., & Ratain, M. J. (2005) · Pharmacogenetics and Genomics · doi:10.1097/01213011-200505000-00004 · Cited by 111
THE EFFECTS OF INBREEDING AT LOCI WITH HETEROZYGOTE ADVANTAGE
Hill, W. G., & Robertson, A. (1968) · Genetics · doi:10.1093/genetics/60.3.615 · Cited by 103
Influence of genetic variants in UGT1A1 and UGT1A9 on the in vivo glucuronidation of SN-38
Singh, A. S., Paoluzzi, L., Price, D. K., Danesi, R., Mathijssen, R. H. J., Verweij, J., Figg, W. D., & Sparreboom, A. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.22.14_suppl.2072 · Cited by 90
Sparreboom, A., de Bruijn, P., de Jonge, M. J. A., Loos, W. J., Stoter, G., Verweij, J., & Nooter, K. (1998) · Journal of Chromatography B Biomedical Sciences and Applications · doi:10.1016/s0378-4347(98)00147-9 · Cited by 78
Wang, Y., Kato, N., Hoshida, Y., Otsuka, M., Taniguchi, H., Moriyama, M., Shiina, S., Kawabe, T., Ito, Y. M., & Omata, M. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-1187-3 · Cited by 68
Phase II Study of Irinotecan Plus Cisplatin in Patients With Advanced Non–Small-Cell Lung Cancer
DeVore, R. F., Johnson, D. H., Crawford, J., Garst, J. L., Dimery, I. W., Eckardt, J. R., Eckhardt, S. G., Elfring, G. L., Schaaf, L. J., Hanover, C. K., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.9.2710 · Cited by 67
Desai, A. A., Innocenti, F., & Ratain, M. J. (2003) · Pharmacogenetics · doi:10.1097/00008571-200308000-00010 · Cited by 66
Grove, A. D., Kessler, F. K., Metz, R. P., et al. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.3.1621 · Cited by 63
Cited by
Delivering affordable cancer care in high-income countries
Sullivan, R., Peppercorn, J., Sikora, K., Zalcberg, J., Meropol, N. J., Amir, E., Khayat, D., Boyle, P., Autier, P., Tannock, I. F., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70141-3 · Cited by 718
UGT1A1*28 Genotype and Irinotecan-Induced Neutropenia: Dose Matters
Hoskins, J. M., Goldberg, R. M., Qu, P., Ibrahim, J. G., & McLeod, H. L. (2007) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djm115 · Cited by 469
de Man, F. M., Goey, A. K. L., van Schaik, R. H. N., Mathijssen, R. H. J., & Bins, S. (2018) · Clinical Pharmacokinetics · doi:10.1007/s40262-018-0644-7 · Cited by 421
Irinotecan, a key chemotherapeutic drug for metastatic colorectal cancer
Fujita, K.-I. (2015) · World Journal of Gastroenterology · doi:10.3748/wjg.v21.i43.12234 · Cited by 323
Minami, H., Sai, K., Saeki, M., Saito, Y., Ozawa, S., Suzuki, K., Kaniwa, N., Sawada, J.-I., Hamaguchi, T., Yamamoto, N., et al. (2007) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e328014341f · Cited by 289
Metadata
- Authors
- Han, J.-Y., Lim, H.-S., Shin, E. S., Yoo, Y.-K., Park, Y. H., Lee, J.-E., Jang, I.-J., Ho Lee, D., & Soo Lee, J.
- Venue
- Journal of Clinical Oncology
- Published
- 2006-05-20
- Volume
- 24
- Issue
- 15
- Pages
- 2237-2244
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W1992918749
- Cited by
- 298
- References
- 36
- FWCI
- 24.66
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.